# A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects

> **NCT05138861** · PHASE1 · COMPLETED · sponsor: **Tarsus Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** TP-03 (Lotilaner Ophthalmic Solution), 0.25%

## Key facts

- **NCT ID:** NCT05138861
- **Lead sponsor:** Tarsus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-09
- **Primary completion:** 2021-09-03
- **Final completion:** 2021-09-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05138861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05138861, "A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05138861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*